Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
Share
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company's largest-ever acquisitions.
More from Australia
Pinnacle Minerals secures option over US tungsten projects
Invex to acquire Rekover Therapeutics in deal
Marmota doubles Greenewood high-grade gold strike length
CZR Resources seeks ASIC consent to cancel takeover
AML3D secures $2.2M Northrop Grumman deal
Beforepay revenue reaches $16.5M in record quarter
